PUBLISHER: TechSci Research | PRODUCT CODE: 2046391
PUBLISHER: TechSci Research | PRODUCT CODE: 2046391
H1N1 Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration, By Type of Brand, By Distribution Channel, By Region & Competition, 2021-2031F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The Global H1N1 Vaccines Market is projected to expand from USD 10.13 billion in 2025 to USD 13.07 billion by 2031, demonstrating a compound annual growth rate of 4.34%. These vaccines, typically found in trivalent or quadrivalent seasonal formulations, are biological agents that prime the immune system to generate antibodies against the influenza A H1N1 virus subtype. The market's growth is primarily fueled by intensive government immunization initiatives and the essential requirement for countries to maintain strategic reserves against respiratory threats with pandemic potential. In 2025, the World Health Organization reported a stable global annual production capacity of around 1.53 billion doses for seasonal influenza vaccines, highlighting the substantial manufacturing effort dedicated to these public health needs. However, this robust capacity faces a significant hurdle due to the laborious and time-consuming nature of traditional egg-based production, which generates logistical constraints that hinder the swift scaling of vaccine availability during unexpected outbreaks and limit immediate industry responsiveness to demand shifts.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 10.13 Billion |
| Market Size 2031 | USD 13.07 Billion |
| CAGR 2026-2031 | 4.34% |
| Fastest Growing Segment | Online Pharmacies |
| Largest Market | North America |
Market Driver
A key growth driver for the Global H1N1 Vaccines Market is the progress in vaccine development technologies, as manufacturers shift from conventional egg-based methods towards advanced platforms such as mRNA and cell-based formulations. This shift is crucial for achieving greater efficacy and quicker production, especially when circulating strains differ from the vaccine viruses. Specifically, mRNA technology has allowed for swift adaptation to viral mutations, providing better protection than standard options. Moderna, for example, reported in June 2025 that its mRNA-1010 candidate showed 29.6% relative vaccine efficacy against A/H1N1 in a Phase 3 trial for adults aged 50 and above. These innovations not only improve clinical results but also boost market competition and investment in better manufacturing facilities. Concurrently, the increasing incidence of H1N1 infections and their impact on healthcare systems necessitate expanded immunization coverage and strategic stockpiling by governments. The recurrence of severe seasonal outbreaks, marked by high hospitalization rates-reaching over 600,000 in the US during the 2024-2025 influenza season, a 15-year peak, as per CDC data reported in July 2025-underscores the need for strong vaccination efforts to manage public health emergencies. This significant epidemiological pressure ensures steady revenue for leading companies, though demand can vary with seasonal intensity; for instance, Sanofi's influenza and COVID-19 vaccine sales reached €1.53 billion in Q3 2025, according to a November 2025 report.
Market Challenge
A major impediment to the Global H1N1 Vaccines Market's expansion is its reliance on time-consuming egg-based manufacturing. This conventional method demands extensive lead times, often exceeding six months, for sourcing pathogen-free eggs and culturing the virus, creating an inflexible supply chain incapable of quickly adapting to sudden demand changes. As a result, during unexpected outbreaks or when rapid vaccine updates are needed due to strain mismatches, the industry encounters significant logistical hurdles. This inability to rapidly scale production leads to critical supply shortages, thereby limiting revenue and preventing manufacturers from fully capitalizing on market opportunities during peak demand. The prevalent use of this legacy technology intensifies market inflexibility; Vaccines Europe reported in 2025 that over 80% of global seasonal and pandemic influenza vaccines utilized traditional egg-based production. This heavy dependence on a slow platform restricts the industry's overall responsiveness, making it susceptible to supply chain disruptions and hindering the adoption of more agile manufacturing approaches. Consequently, the market's growth is consistently constrained by the inherent physical and temporal limitations of its main production method, impeding its ability to fully address evolving global public health needs.
Market Trends
Current market trends include the development of combined COVID-19 and H1N1 influenza formulations, which aim to combat vaccine fatigue and simplify immunization efforts. Manufacturers are integrating H1N1 antigens with SARS-CoV-2 components to offer single-dose solutions effective against both viruses during the respiratory season. This strategy improves patient convenience and ensures strong immune responses against both pathogens, vital for public health adherence. For instance, Novavax reported in June 2025 that its combination candidate generated robust immune responses in Phase 3 trials, with antibody levels 2.4 to 5.7 times above baseline. This highlights the industry's dedication to broad population coverage via streamlined vaccination. Furthermore, the market is increasingly shifting towards cell-based manufacturing to avoid egg-adaptive mutations that can compromise vaccine efficacy. Cell-based platforms prevent H1N1 virus mutation during production, ensuring a precise antigenic match to wild-type strains-an advantage over traditional egg-based methods. Real-world data supports this shift, with CSL Seqirus reporting in October 2025 that cell-based vaccines showed a 19.8% relative improvement in effectiveness against test-confirmed influenza compared to egg-based formulations. This drives the industry's adoption of more dependable non-egg technologies to guarantee optimal antigen authenticity.
Key Market Players
- AstraZeneca PLC
- Sanofi Pasteur MSD AG
- GSK PLC
- Abbott Laboratories Inc
- CSL Ltd
- Pfizer Inc
- CPL Biologicals Pvt Ltd
- Mitsubishi Tanabe Pharma Corp
- Sinovac Biotech Co Ltd
- Zydus Lifesciences Ltd
Report Scope
In this report, the Global H1N1 Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
H1N1 Vaccines Market, By Route of Administration
- Intradermal Vaccines
- Intramuscular Vaccines
- Intranasal Vaccines
H1N1 Vaccines Market, By Type of Brand
- Agripal
- Fiuarix
- Influgen
- Influvac
- Nasovac
- Vaxigrip
H1N1 Vaccines Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
H1N1 Vaccines Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global H1N1 Vaccines Market.
Available Customizations:
Global H1N1 Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global H1N1 Vaccines Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
- 5.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
- 5.3. Market Map
6. North America H1N1 Vaccines Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Route of Administration
- 6.2.2. By Type of Brand
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States H1N1 Vaccines Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Route of Administration
- 6.3.1.2.2. By Type of Brand
- 6.3.1.2.3. By Distribution Channel
- 6.3.1.1. Market Size & Forecast
- 6.3.2. Canada H1N1 Vaccines Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.1.1. By Value
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Route of Administration
- 6.3.2.2.2. By Type of Brand
- 6.3.2.2.3. By Distribution Channel
- 6.3.2.1. Market Size & Forecast
- 6.3.3. Mexico H1N1 Vaccines Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.1.1. By Value
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Route of Administration
- 6.3.3.2.2. By Type of Brand
- 6.3.3.2.3. By Distribution Channel
- 6.3.3.1. Market Size & Forecast
- 6.3.1. United States H1N1 Vaccines Market Outlook
7. Europe H1N1 Vaccines Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Route of Administration
- 7.2.2. By Type of Brand
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany H1N1 Vaccines Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Route of Administration
- 7.3.1.2.2. By Type of Brand
- 7.3.1.2.3. By Distribution Channel
- 7.3.1.1. Market Size & Forecast
- 7.3.2. France H1N1 Vaccines Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Route of Administration
- 7.3.2.2.2. By Type of Brand
- 7.3.2.2.3. By Distribution Channel
- 7.3.2.1. Market Size & Forecast
- 7.3.3. United Kingdom H1N1 Vaccines Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Route of Administration
- 7.3.3.2.2. By Type of Brand
- 7.3.3.2.3. By Distribution Channel
- 7.3.3.1. Market Size & Forecast
- 7.3.4. Italy H1N1 Vaccines Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.1.1. By Value
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Route of Administration
- 7.3.4.2.2. By Type of Brand
- 7.3.4.2.3. By Distribution Channel
- 7.3.4.1. Market Size & Forecast
- 7.3.5. Spain H1N1 Vaccines Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Route of Administration
- 7.3.5.2.2. By Type of Brand
- 7.3.5.2.3. By Distribution Channel
- 7.3.5.1. Market Size & Forecast
- 7.3.1. Germany H1N1 Vaccines Market Outlook
8. Asia Pacific H1N1 Vaccines Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Route of Administration
- 8.2.2. By Type of Brand
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. Asia Pacific: Country Analysis
- 8.3.1. China H1N1 Vaccines Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Route of Administration
- 8.3.1.2.2. By Type of Brand
- 8.3.1.2.3. By Distribution Channel
- 8.3.1.1. Market Size & Forecast
- 8.3.2. India H1N1 Vaccines Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Route of Administration
- 8.3.2.2.2. By Type of Brand
- 8.3.2.2.3. By Distribution Channel
- 8.3.2.1. Market Size & Forecast
- 8.3.3. Japan H1N1 Vaccines Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Route of Administration
- 8.3.3.2.2. By Type of Brand
- 8.3.3.2.3. By Distribution Channel
- 8.3.3.1. Market Size & Forecast
- 8.3.4. South Korea H1N1 Vaccines Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Route of Administration
- 8.3.4.2.2. By Type of Brand
- 8.3.4.2.3. By Distribution Channel
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Australia H1N1 Vaccines Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Route of Administration
- 8.3.5.2.2. By Type of Brand
- 8.3.5.2.3. By Distribution Channel
- 8.3.5.1. Market Size & Forecast
- 8.3.1. China H1N1 Vaccines Market Outlook
9. Middle East & Africa H1N1 Vaccines Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Route of Administration
- 9.2.2. By Type of Brand
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
- 9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia H1N1 Vaccines Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Route of Administration
- 9.3.1.2.2. By Type of Brand
- 9.3.1.2.3. By Distribution Channel
- 9.3.1.1. Market Size & Forecast
- 9.3.2. UAE H1N1 Vaccines Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Route of Administration
- 9.3.2.2.2. By Type of Brand
- 9.3.2.2.3. By Distribution Channel
- 9.3.2.1. Market Size & Forecast
- 9.3.3. South Africa H1N1 Vaccines Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Route of Administration
- 9.3.3.2.2. By Type of Brand
- 9.3.3.2.3. By Distribution Channel
- 9.3.3.1. Market Size & Forecast
- 9.3.1. Saudi Arabia H1N1 Vaccines Market Outlook
10. South America H1N1 Vaccines Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Route of Administration
- 10.2.2. By Type of Brand
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil H1N1 Vaccines Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Route of Administration
- 10.3.1.2.2. By Type of Brand
- 10.3.1.2.3. By Distribution Channel
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Colombia H1N1 Vaccines Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Route of Administration
- 10.3.2.2.2. By Type of Brand
- 10.3.2.2.3. By Distribution Channel
- 10.3.2.1. Market Size & Forecast
- 10.3.3. Argentina H1N1 Vaccines Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Route of Administration
- 10.3.3.2.2. By Type of Brand
- 10.3.3.2.3. By Distribution Channel
- 10.3.3.1. Market Size & Forecast
- 10.3.1. Brazil H1N1 Vaccines Market Outlook
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Global H1N1 Vaccines Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products
15. Competitive Landscape
- 15.1. AstraZeneca PLC
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
- 15.2. Sanofi Pasteur MSD AG
- 15.3. GSK PLC
- 15.4. Abbott Laboratories Inc
- 15.5. CSL Ltd
- 15.6. Pfizer Inc
- 15.7. CPL Biologicals Pvt Ltd
- 15.8. Mitsubishi Tanabe Pharma Corp
- 15.9. Sinovac Biotech Co Ltd
- 15.10. Zydus Lifesciences Ltd
16. Strategic Recommendations
17. About Us & Disclaimer
